挑战传统观点:经阴道网片与致癌风险无关
该研究利用纽约州行政数据,纳入2008年1月至2009年12月期间接受经阴道网片植入术治疗盆腔器官脱垂或压力性尿失禁的女性,按合并症和手术日期匹配对照队列。中位随访6年(范围5至7年),结果显示经阴道网片植入与1年及整个随访期间癌症诊断风险增加无关。
要点
- 经阴道网片植入与1年及整个随访期间盆腔/局部癌症或任何癌症诊断风险增加无关。
- 中位随访6年(范围5至7年),网片植入未增加恶性肿瘤发生风险。
- 研究基于纽约州行政数据,匹配对照包括胆囊切除术和子宫切除术队列。
核心结论
- 经阴道网片植入手术与中位随访6年时的恶性肿瘤发生无关。
研究设计与样本
- 利用纽约州行政数据,通过ICD-9-CM手术操作码和CPT-4编码识别2008年1月至2009年12月期间因盆腔器官脱垂或压力性尿失禁接受经阴道网片手术的女性。
- 网片队列患者按合并症和手术日期与2个对照队列进行个体匹配。
- 共纳入2,229例接受网片盆腔器官脱垂手术的患者和10,401例接受压力性尿失禁吊带手术的患者。
- 匹配后盆腔器官脱垂网片与胆囊切除术组1,870对(1:2),盆腔器官脱垂网片与子宫切除术组1,278对(1:1),吊带与胆囊切除术组7,986对(1:1),吊带与子宫切除术组3,810对(1:1)。
- 中位随访6年(范围5至7年)。
主要发现
- 经阴道网片植入与1年时及整个随访期间(最长7年)癌症诊断(盆腔/局部癌症或任何癌症)风险增加无关。
- 研究未发现网片植入与癌症诊断风险增加存在关联。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We sought to determine if there was a potential link between synthetic polypropylene mesh implantation for transvaginal pelvic organ prolapse and stress urinary incontinence, and carcinogenesis using statewide administrative data. MATERIALS AND METHODS: Women who underwent transvaginal surgery for pelvic organ prolapse or stress urinary incontinence with mesh between January 2008 and December 2009 in New York State were identified using ICD-9-CM procedure codes and CPT-4 codes. Patients in the mesh cohort were individually matched to 2 control cohorts based on comorbidities and procedure date. Carcinogenesis was determined before and after matching at 1, 2 and 3 years, and during the entire followup time. RESULTS: A total of 2,229 patients who underwent mesh based pelvic organ prolapse surgery and 10,401 who underwent sling surgery for stress urinary incontinence between January 2008 and December 2009 were included in the study. Mean followup was 6 years (range 5 to 7). Exact matching between the mesh and control cohorts resulted in 1,870 pairs for pelvic organ prolapse mesh and cholecystectomy (1:2), 1,278 pairs for pelvic organ prolapse mesh and hysterectomy (1:1), 7,986 pairs for sling and cholecystectomy (1:1) and 3,810 pairs for sling and hysterectomy (1:1). Transvaginal mesh implantation was not associated with an increased risk of a cancer diagnosis (pelvic/local cancers or any cancer) at 1 year and during the entire followup of up to 7 years. CONCLUSIONS: Transvaginal surgery with implantation of mesh was not associated with the development of malignancy at a mean followup of 6 years.
引用
- Chughtai B, Sedrakyan A, Mao J, et al. Challenging the Myth: Transvaginal Mesh is Not Associated with Carcinogenesis. J Urol. 2017. PMID: 28479238. doi:10.1016/j.juro.2017.04.099
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。